CN115529826A - 经掩蔽的il12融合蛋白及其使用方法 - Google Patents

经掩蔽的il12融合蛋白及其使用方法 Download PDF

Info

Publication number
CN115529826A
CN115529826A CN202180030714.5A CN202180030714A CN115529826A CN 115529826 A CN115529826 A CN 115529826A CN 202180030714 A CN202180030714 A CN 202180030714A CN 115529826 A CN115529826 A CN 115529826A
Authority
CN
China
Prior art keywords
polypeptide
masked
fusion protein
linker
fused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180030714.5A
Other languages
English (en)
Chinese (zh)
Inventor
R·布莱克勒
G·沃尔克斯
D·斗达
T·斯普雷特冯克罗伊登斯泰因
G·德斯贾丁斯
N·阿法坎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeast Biopharmaceutical Co ltd
Original Assignee
Yeast Biopharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeast Biopharmaceutical Co ltd filed Critical Yeast Biopharmaceutical Co ltd
Publication of CN115529826A publication Critical patent/CN115529826A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN202180030714.5A 2020-03-23 2021-03-23 经掩蔽的il12融合蛋白及其使用方法 Pending CN115529826A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062993334P 2020-03-23 2020-03-23
US62/993,334 2020-03-23
US202163146567P 2021-02-05 2021-02-05
US63/146,567 2021-02-05
PCT/CA2021/050383 WO2021189139A1 (en) 2020-03-23 2021-03-23 Masked il12 fusion proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
CN115529826A true CN115529826A (zh) 2022-12-27

Family

ID=77890776

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180030714.5A Pending CN115529826A (zh) 2020-03-23 2021-03-23 经掩蔽的il12融合蛋白及其使用方法

Country Status (10)

Country Link
US (1) US20230122079A1 (https=)
EP (1) EP4126972A4 (https=)
JP (1) JP7773991B2 (https=)
KR (1) KR20230024252A (https=)
CN (1) CN115529826A (https=)
AU (1) AU2021240872A1 (https=)
BR (1) BR112022019020A2 (https=)
CA (1) CA3147126A1 (https=)
MX (1) MX2022011676A (https=)
WO (1) WO2021189139A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116096738A (zh) * 2020-05-19 2023-05-09 狼人治疗公司 可活化il-12多肽及其使用方法
WO2025007838A1 (zh) * 2023-07-04 2025-01-09 礼邦医药(香港)有限公司 Klk1融合蛋白的制备方法
WO2025077875A1 (zh) * 2023-10-13 2025-04-17 英脉德医疗科技(广东)有限公司 肿瘤微环境特异激活的cd47抗体

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI880235B (zh) 2017-11-28 2025-04-11 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
JP7771076B2 (ja) * 2020-04-01 2025-11-17 エクシリオ デベロップメント， インコーポレイテッド マスクされたｉｌ－１２サイトカイン及びその切断産物
WO2021207669A1 (en) 2020-04-10 2021-10-14 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
WO2022155263A2 (en) * 2021-01-12 2022-07-21 Askgene Pharma Inc. Chimeric molecules comprising il-12 agonist polypeptide
BR112023018735A2 (pt) 2021-03-16 2023-11-28 Cytomx Therapeutics Inc Construtos de citocinas ativáveis mascarados e composições e métodos relacionados
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
WO2023050006A1 (en) * 2021-09-29 2023-04-06 Zymeworks Bc Inc. Modified interleukin p40 subunit proteins and methods of use thereof
EP4466290A4 (en) * 2022-01-20 2026-02-11 Repertoire Immune Medicines Inc IL-12 FUSION PROTEINS TARGETING CD8
US20250114489A1 (en) * 2022-02-15 2025-04-10 Tagworks Pharmaceuticals B.V. Masked il12 protein
AU2023226005A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
WO2024148369A1 (en) * 2023-01-07 2024-07-11 Lyell Immunopharma, Inc. Targeted il-12 affinity variants
US20240376170A1 (en) 2023-01-11 2024-11-14 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
IL322055A (en) * 2023-01-13 2025-09-01 Regeneron Pharma IL12 receptor agonists and methods of using them
EP4704979A1 (en) * 2023-01-20 2026-03-11 Boehringer Ingelheim International GmbH Il-12 fc fusion proteins
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
TW202523680A (zh) * 2023-12-07 2025-06-16 大陸商上海藥明生物技術有限公司 針對ｉｌ－１２受體的異二聚體蛋白
WO2025122957A1 (en) * 2023-12-08 2025-06-12 Amunix Pharmaceuticals, Inc. Protease activatable cytokines and methods for making and using the same
WO2025136986A2 (en) 2023-12-18 2025-06-26 Genzyme Corporation Il-12 loss of potency muteins
CN117838836B (zh) * 2024-01-11 2024-06-28 广州医科大学附属第二医院 白介素39在防治血小板减少症中的应用
WO2025160083A1 (en) * 2024-01-22 2025-07-31 Onko-Innate Pty Ltd Targeted low potency il-12 fc fusion proteins and uses thereof
WO2025242836A1 (en) * 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
WO2025242835A1 (en) * 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026020161A1 (en) * 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods
WO2026083295A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010081173A2 (en) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
WO2019173832A2 (en) * 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
WO2019222296A1 (en) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41374A (fr) * 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
CN109071653A (zh) * 2016-03-29 2018-12-21 詹森生物科技公司 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
BR112019005964A2 (pt) * 2016-09-27 2019-06-18 Epicentrx, Inc. proteínas de fusão imunomoduladoras
AU2019288484B2 (en) * 2018-06-22 2024-06-20 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
SG11202013248YA (en) * 2018-07-31 2021-02-25 Amgen Inc Pharmaceutical formulations of masked antibodies
US20220002370A1 (en) * 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
WO2020160189A1 (en) * 2019-01-29 2020-08-06 Gritstone Oncology, Inc. Multispecific binding proteins
AU2020353235A1 (en) * 2019-09-28 2022-03-31 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
CN110777115B (zh) 2019-11-21 2020-08-21 北京启辰生生物科技有限公司 用于促进辅助T细胞产生TNF-α细胞因子的工程化DC细胞及方法
WO2022016270A1 (en) * 2020-07-20 2022-01-27 Zymeworks Inc. Fusion proteins comprising a ligand-receptor pair and a biologically functional protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010081173A2 (en) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
WO2019173832A2 (en) * 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
WO2019222296A1 (en) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116096738A (zh) * 2020-05-19 2023-05-09 狼人治疗公司 可活化il-12多肽及其使用方法
WO2025007838A1 (zh) * 2023-07-04 2025-01-09 礼邦医药(香港)有限公司 Klk1融合蛋白的制备方法
CN119546286A (zh) * 2023-07-04 2025-02-28 礼邦医药(香港)有限公司 Klk1融合蛋白的制备方法
WO2025077875A1 (zh) * 2023-10-13 2025-04-17 英脉德医疗科技(广东)有限公司 肿瘤微环境特异激活的cd47抗体

Also Published As

Publication number Publication date
JP7773991B2 (ja) 2025-11-20
US20230122079A1 (en) 2023-04-20
BR112022019020A2 (pt) 2023-02-07
JP2023518518A (ja) 2023-05-01
AU2021240872A1 (en) 2022-11-17
EP4126972A4 (en) 2024-05-01
CA3147126A1 (en) 2021-09-30
MX2022011676A (es) 2023-03-08
KR20230024252A (ko) 2023-02-20
WO2021189139A1 (en) 2021-09-30
EP4126972A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
JP7773991B2 (ja) マスクされたｉｌ１２融合タンパク質及びその使用方法
TWI589591B (zh) 雙特異性ｔ細胞活化抗原結合分子
JP7846668B2 (ja) リガンド－受容体対及び生物学的に機能的なタンパク質を含む融合タンパク質
US20230357431A1 (en) Improved antigen binding receptors
TW202204409A (zh) Ｄｌｌ３靶向之多特異性抗原結合分子及其用途
CN114127123A (zh) 结合cea的抗体与4-1bbl的融合
TW202219065A (zh) 免疫活化 Fc 域結合分子
JP2017504328A (ja) 二重特異性ｃｄ３及びｃｄ１９抗原結合構築物
US20240228567A1 (en) Modified interleukin p40 subunit proteins and methods of use thereof
TW202204410A (zh) 免疫活化多特異性抗原結合分子及其用途
US20230121511A1 (en) Method for producing multispecific antigen-binding molecules
EP3864051A1 (en) Antibody constructs binding 4-1bb and tumor-associated antigens and uses thereof
HK40085919A (en) Masked il12 fusion proteins and methods of use thereof
HK40110021A (zh) 经修饰的白细胞介素p40亚基蛋白质及其使用方法
HK40119034A (zh) 干扰素γ变体以及包含这些变体的抗原结合分子
HK40091599A (zh) 免疫活化fc结构域结合分子
HK40075193A (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
CN119095880A (zh) 干扰素γ变体以及包含这些变体的抗原结合分子
CN121127493A (zh) 靶向干扰素 α 融合蛋白及使用方法
CN116997362A (zh) 含调节免疫细胞功能的cd8抗原结合分子的融合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40085919

Country of ref document: HK

CB02 Change of applicant information

Address after: British Columbia

Applicant after: Enzymatic British Columbia Ltd.

Address before: British Columbia

Applicant before: Yeast Biopharmaceutical Co.,Ltd.

CB02 Change of applicant information